Drugs / suraxavir
suraxavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05814926 | Apr → Aug 2023 | — | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | suraxavir | “Suraxavir marboxil (GP681, abbreviated as suraxavir) is a novel, orally active small-molecule polymerase acidic (PA) inhibitor for the treatment of influenza.” PMID 41870058 ↗ Mar 2026 |
| Known as | GP681 | “Suraxavir marboxil (GP681, abbreviated as suraxavir) is a novel, orally active small-molecule polymerase acidic (PA) inhibitor for the treatment of influenza.” PMID 41870058 ↗ Mar 2026 |
| Known as | Suraxavir marboxil | “Suraxavir marboxil (GP681, abbreviated as suraxavir) is a novel, orally active small-molecule polymerase acidic (PA) inhibitor for the treatment of influenza.” PMID 41870058 ↗ Mar 2026 |
| Modality | Small molecule | “Suraxavir marboxil (GP681, abbreviated as suraxavir) is a novel, orally active small-molecule polymerase acidic (PA) inhibitor for the treatment of influenza.” PMID 41870058 ↗ Mar 2026 |
| Route | Oral | “Subjects with mild or moderate hepatic impairment and matched healthy controls (n = 8 per group) received a single oral dose of 40 mg suraxavir.” PMID 41870058 ↗ Mar 2026 |